Text Size

Antiretroviral Switch From Didanosine to Tenofovir in HIV/HCV Co-infected Patients

This study has been completed.
Sponsor:
Collaborator:
Health Canada
Information provided by:
University of British Columbia
ClinicalTrials.gov Identifier:
NCT00358696
First received: July 28, 2006
Last updated: October 19, 2009
Last verified: October 2009
History of Changes
  Purpose

The primary purpose of this study is to evaluate the impact of changing didanosine in an effective anti-HIV regimen to tenofovir on virologic suppression. We hypothesize that, in patients with maximal virologic suppression on a double class regimen (including two NRTIs and an NNRTI or a PI, boosted with RTV or not), a single drug substitution of didanosine for tenofovir will represent a viable strategy without any negative impact on the virologic efficacy of the regimen.


Condition Intervention Phase
HIV
HIV Infections
 Drug: tenofovir
 Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: TEN Switch - An Observational Phase IV Study to Evaluate the Safety and Efficacy of Substituting Tenofovir for Didanosine in Virologically Controlled HIV-infected Patients Co-infected With Hepatitis C Virus.

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of British Columbia:

Primary Outcome Measures:
  • Virologic Suppression [ Time Frame: Unspecified ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • HAART adherence, safety, CD4 cell count [ Time Frame: Unspecified ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: July 2006
Study Completion Date: October 2009
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: tenofovir
    See Detailed Description.
Detailed Description:

Primary objective - to determine the impact of changing part of an effective HAART regimen to tenofovir on maintenance of virologic suppression in HCV co-infected patients.

Secondary objective - to assess the safety and tolerability over 12 weeks in patients switched to tenofovir.

Research Method - This will be a single arm observational study to include 30 subjects. Patients requiring HCV treatment will be assessed and patients receiving didanosine will be clinically evaluated to determine an appropriate NRTI drug switch. Patients who are to switch the didanosine component of their regimen to tenofovir will be eligible to participate in the study and will be followed for a period of observation of up to 4 weeks. All patients will be receiving tenofovir as one capsule, once daily. The primary endpoint will be maintenance of virologic suppression between the Baseline visit and week 12 in the overall study group. Measures of adherence to HAART, safety, tolerability and CD4 cell counts will also be obtained at each study visit, and will constitute secondary study endpoints.

  Eligibility

Ages Eligible for Study:   19 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Be age 19 or older;
  2. Have a confirmed diagnosis of HIV infection;
  3. Have a confirmed positive HCV RNA PCR;
  4. Have two consecutive HIV RNA levels <50 copies/mL with the most recent within the past 3 months;
  5. Must not exhibit evidence of an acute illness, including an acute opportunistic infection;
  6. Must not have any evidence of grade 3-4 laboratory abnormalities;
  7. Must be able and willing to provide informed consent.

Exclusion Criteria:

  1. Be receiving investigational drug within 30 days prior to beginning this study;
  2. If female, be pregnant or breast-feeding;
  3. In the opinion of the investigator, is unlikely to comply with the study protocol or is unsuitable for participation for any reason.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00358696

Locations
Canada, British Columbia
Pender Community Health Centre
Vancouver, British Columbia, Canada
Sponsors and Collaborators
University of British Columbia
Health Canada
Investigators
Principal Investigator: Dr. Brian Conway, MD University of British Columbia
  More Information

No publications provided

Responsible Party: Dr. Brian Conway, University of British Columbia
ClinicalTrials.gov Identifier: NCT00358696     History of Changes
Other Study ID Numbers: C05-0218
Study First Received: July 28, 2006
Last Updated: October 19, 2009
Health Authority: Canada: Health Canada

Keywords provided by University of British Columbia:
tenofovir
didanosine
hiv
hepatitis c virus infection
treatment

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Hepatitis C
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Hepatitis, Viral, Human
Flaviviridae Infections
Hepatitis
 Liver Diseases
Digestive System Diseases
Didanosine
Tenofovir
Tenofovir disoproxil
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on March 03, 2013